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Objective: The aim of this study was to determine the efﬁcacy and safety of luteal phase support using
human chorionic gonadotropin (hCG) in cycles that are triggered with a gonadotropin-releasing hor-
mone (GnRH) agonist in a moderate-to-high risk population undergoing a GnRH antagonist protocol.
Materials and methods: We retrospectively reviewed the charts of patients undergoing an in vitro
fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycle with a GnRH antagonist protocol from
September 2011 to August 2012. The patients were deﬁned as at high risk for ovarian hyperstimulation
syndrome (OHSS) in terms of anti-Müllerian hormone (AMH) and antral follicle counts (AFCs). The pa-
tients were divided into two groups depending on whether ovulation was triggered with hCG or a GnRH
agonist. Modiﬁed luteal support was provided for the cycles triggered by the GnRH agonist via low dose
hCG (1500~5000 IU). For the cycles that were triggered by hCG, urinary hCG (5000 IU) following two
doses of recombinant hCG (250 mg) were administered. The primary outcomes of this study were the
clinical pregnancy rate and the OHSS rate of the two groups. The secondary outcomes were the number
of oocytes retrieved and the number of good quality embryos obtained.
Results: The study group and the control group were similar in terms of the primary and secondary
outcome measures.
Conclusion: Aggressive luteal support with low dose hCG following a GnRH agonist trigger can result in a
comparable pregnancy rate to that with the use of a traditional hCG ovulation trigger. However, OHSS can
still occur in patients with risk factors. Therefore, other OHSS prevention strategies should be considered.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Ovarian hyperstimulation syndrome (OHSS) is one of the most
common iatrogenic side effects of controlled ovarian hyperstim-
ulation. The incidence of the more severe forms of OHSS can reach
3.1e8% [1]. For the primary prevention of OHSS, high-risk patients
are identiﬁed to individualize ovarian stimulation. The methods of
individualization include choosing the proper protocol andnd Gynecology, Chang Gung
yuan, 333, Taiwan.
ang).
bstetrics & Gynecology. Publishedminimizing the gonadotropin dose required to achieve adequate
oocyte maturation. A meta-analysis found that patients who are
treated with a gonadotropin-releasing hormone (GnRH) antago-
nist have signiﬁcantly shorter ovarian stimulations, receive lower
dose of gonadotropins, and exhibit fewer growing follicles [2].
Consequently, the incidence of severe OHSS is signiﬁcantly
reduced, and the interventions required to prevent OHSS are
decreased [2]. In contrast, the pituitary gland remains responsive
to GnRH agonists when GnRH antagonists are introduced to pre-
vent a premature luteinizing hormone (LH) surge. Thus, GnRH
agonists represent an alternative ovulation trigger in a GnRH
antagonist-based protocol.by Elsevier Taiwan LLC. All rights reserved.
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and embryo qualities are obtained independent of whether the
ﬁnal oocyte maturation is triggered by human chorionic gonado-
tropin (hCG) or a GnRH agonist. Moreover, GnRH agonists have the
advantages of producing follicle-stimulating hormone (FSH) surges
that are more similar to the natural cycle and reducing the risk of
OHSS [3]. However, cycles triggered with GnRH agonists have been
associated with poor clinical outcomes and extremely high early
pregnancy loss rates in early randomized control trials [3e5]. Ac-
cording to the current literature, these phenomena seem to be
associated with the inadequate luteal support caused by early
luteolysis [6]. Therefore, modiﬁed luteal support methods,
including low dose hCG, recombinant LH, and intensive estrogen
and progesterone, have been proposed in some studies [7e11].
In a study conducted by Emperaire et al [12], patients with luteal
phase defects in intrauterine insemination (IUI) cycles triggered by
a GnRH agonist (triptorelin 0.1 mg) were randomized to different
ovulation triggers that primarily varied in terms of triptorelin dose
and frequency and the addition of luteal support. Although this
study concluded that luteal phase defects might be related to pa-
tient characteristics, none of the patients in the group received hCG
12 hours after ovulation triggering for luteal support developed
luteal phase defects [12]. Moreover, another study found that pa-
tients who received 1500 IU hCG 35 hours after GnRH agonist
ovulation triggering exhibited a pregnancy rate comparable to
those who received hCG for ovulation triggering [9]. Subsequent
randomized studies revealed that low dose hCG for luteal support
signiﬁcantly reduces the occurrence of severe OHSS without
compromising pregnancy rate [7,10]. Based on these ﬁndings, our
study sought to examine the efﬁcacy and safety of protocols
involving GnRH agonist ovulation triggers and low dose hCG for
luteal support in patients at high risk for OHSS.
Materials and methods
Patient selection
We retrospectively reviewed the charts of patients who under-
went in vitro fertilization (IVF) or intracytoplasmic sperm injection
(ICSI) cycles with GnRH antagonist protocols from September 2011
to August 2012. Patients were deﬁned as being at a high risk of
OHSS and were included in this study if their antral follicle count
(AFC) was 15 or their anti-Müllerian hormone (AMH) was
3.4 ng/mL according to previous studies [13,14]. Only the ﬁrst
cycle of each patient was included in the study. The only exclusion
criterion was a low response following a standard dose of FSH
stimulation according to the Bologna criteria (i.e., <3 oocytes
retrieved and an E2 level <500 pg/mL on the day of the ovulation
trigger) [15].
Protocol design
All patients received daily doses of 150e250 IU of FSH (Gonal-F,
Merck Serono, Modugno, Italy or Puregon, N.V. Organon, Oss, The
Netherlands) or human menopausal gonadotropin (Menopur, Fer-
ring, Lausanne, Switzerland) for ovarian stimulation according to
the physician's experience. Premature LH surges were prevented
with 0.25 mg of the GnRH antagonist (Centriotide, Merk Serono) on
stimulation Day 5 until the day of ovulation trigger. When at least
two leading follicles were >1.6 cm, the ovulation trigger was given.
The patients were divided into two groups according to the
ovulation trigger employed: 10,000 IU hCG (Pregnyl; N.V. Organon,
Oss, Netherlands), or GnRH agonist (Decapeptyl 2.0 mg, Ferring or
Luprelide 2.5 mg; Takeda, Osaka, Japan). Oocyte retrieval was per-
formed 34 hours after ovulation trigger. The collected oocytes wereinseminated via IVF or ICSI, according to the condition of sperm.
The embryos were transferred between Day 2 and Day 5, and the
numbers of embryos transferred ranged from one to four.
Nearly all of the patients received micronized progesterone
(800mg, Utrogestan; Besins International Belgique S.A., Drogenbos,
Belgium) orally or vaginally and estradiol valerate (4~12 mg,
Estrade, Synmosa, Hsinchu, Taiwan) orally daily for 14 days after
embryo transfer. In the hCG group, 5000 IU urinary hCG was
administered on the day of embryo transfer. Two doses of 250 mg
recombinant hCG (Ovidrel, Merk Serono) were given every other
day thereafter if no clinical symptoms of OHSS, such as nausea,
vomiting, ascites, etc., were observed. Modiﬁed luteal support for
the cycles triggered by the GnRH agonist was provided with
intramuscular injection of progesterone (50 mg) every other day or
single dose intramuscular injection of hydroxyprogesterone cap-
roate (125 mg, Progeston depot, Fuji Pharma, Tokyo, Japan) and
urinary hCG (1500e5000 IU) every other day until Day 8 following
oocyte retrieval. The primary outcomes were the clinical pregnancy
rate and the incidence of OHSS of at least moderate severity. The
secondary outcomes were the numbers of oocytes retrieved and
the numbers of good quality embryos obtained. To further increase
similarity of the two groups in terms of OHSS risk, we concurrently
analyzed patients with AFCs 15 and AMHs 3.4 ng/mL.
Diagnosis of OHSS
The diagnosis and severity determination of OHSS were per-
formed according to the grading system developed by Navot et al
[16]. Moderate OHSS was deﬁned by the presence of ascites and
enlarged ovaries of 8e12 cm. Severe OHSS was deﬁned by the
presence of ascites and enlarged ovaries with or without hydro-
thorax, edema, oliguria, hematocrit levels >45%, WBC counts
>15,000/mL, a serum Creatinine (Cr) of 1e1.5 mg/dL, and abnormal
results of liver function tests. Early and late onset OHSS were
differentiated by the occurrence of symptoms before or after 10
days following the ovulation trigger.
Data analyses
The primary outcomes of this study were the clinical pregnancy
rates and the OHSS rates of the two groups. The secondary out-
comes were the numbers of oocytes and good quality embryos
obtained. The data were processed using the SPSS version 19.0
(IBM, Somers, NY, USA). Analyses of variance and Student t tests
were used to compare the outcomes between the two groups. A
value of p < 0.05 was considered signiﬁcant.
Results
A total of 19 patients were included in the GnRH agonist trigger
group, and 63 patients were included in the hCG trigger group from
September 2011 to August 2012. In terms of basic backgrounds, the
two groups were similar in age, body mass index (BMI), Day 3 FSH,
AMH and AFC (Table 1). The clinical outcomes of the two groups are
listed in Table 2. After ovulation trigger, the average numbers of
oocytes obtained were 15.2/cycle in the GnRH agonist trigger group
and 12.2/cycle in the hCG trigger group (p¼ 0.84). The 2 pronuclear
stage (2PN) embryo yields were 7.7 in the GnRH agonist trigger
group and 6.3 in the hCG trigger group (p ¼ 0.65). The average
numbers of embryos transferred were 2.84 in the GnRH agonist
trigger group and 2.89 in the hCG trigger group (p ¼ 0.37). The
overall pregnancy rates were 58% in the GnRH agonist trigger group
and 52% in the hCG trigger group (p¼ 0.32). Three patients (16%) in
the GnRH agonist trigger group and ﬁve (8%) in the hCG trigger
group developed OHSS (p ¼ 0.56). Among these patients, one (5.2
Table 1
Basic data for the patients meeting the inclusion criteria of AFCs 15 or AMH levels
3.4 ng/mL.
GnRH agonist
(n ¼ 19)
hCG group
(n ¼ 63)
pa
Age (y) 33.6 ± 4.9 34.1 ± 3.8 0.08
BMI (kg/m2) 20.4 ± 2.4 21.3 ± 2.6 0.39
Day 3 FSH (mIU/mL) 6.5 ± 1.9 7.2 ± 2.6 0.70
AMH (ng/mL) 7.5 ± 3.6 6.1 ± 3.3 0.18
AFC 15.7 ± 3.6 12.3 ± 4.3 0.24
FSH dose used (IU) 1543 ± 461 1873 ± 580 0.30
hCG day E2 (pg/mL) 2552 ± 994 1713 ± 937 0.42
Values are expressed as the mean ± standard deviation.
AFC ¼ antral follicle count; AMH ¼ anti-Müllerian hormone; BMI ¼ body mass in-
dex; FSH ¼ follicle-stimulatin hormone; hCG ¼ human chorionic gonadotropin;
GnRH ¼ gonadotropin-releasing hormone.
a Calculated by t test.
Table 2
Clinical results following ovulation trigger for the patients with AFCs 15 or AMH
levels 3.4 ng/mL.
GnRH agonist
(n ¼ 19)
hCG group
(n ¼ 63)
pb
Oocytes retrieveda 15.2 ± 5.9 12.2 ± 6.3 0.84
MII oocytesa 11.3 ± 1.3 8.8 ± 0.7 0.08
2PNa 7.7 ± 4.4 6.3 ± 3.6 0.65
No. of embryos transferreda 2.8 ± 0.9 2.9 ± 0.8 0.37
Pregnancy rate (%) 58 52 0.32
OHSS rate (%) 16 8 0.06
Severe OHSS (%) 11 6 0.24
hCG ¼ human chorionic gonadotropin; GnRH ¼ gonadotropin-releasing hormone;
MII ¼ Metaphase II; 2PN ¼ 2 pronuclear stage embryos; OHSS ¼ ovarian hyper-
stimulation syndrome.
a Values are expressed as mean ± standard deviation.
b Calculated by t test.
Table 4
Clinical results following ovulation trigger among patients with both AFCs 15 and
AMH levels 3.4 ng/mL.
GnRH agonist
(n ¼ 12)
hCG group
(n ¼ 13)
pb
Oocyte retrieveda 15.5 ± 6.6 16.2 ± 6.9 0.80
MII oocytesa 11.8 ± 1.7 9.8 ± 1.2 0.33
2PNa 8.7 ± 4.8 8.1 ± 3.6 0.32
No. of embryos transferreda 2.8 ± 0.9 2.8 ± 0.7 0.50
Pregnancy rate (%) 50 62 0.44
OHSS rate (%) 25 23 0.83
Severe OHSS (%) 17 16 0.87
hCG ¼ human chorionic gonadotropin; GnRH ¼ gonadotropin-releasing hormone;
MII ¼ Metaphase II; 2PN ¼ 2 pronuclear stage embryos; OHSS ¼ ovarian hyper-
stimulation syndrome.
a Values are expressed as mean ± standard deviation.
b Calculated by t test.
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group exhibited early onset OHSS. Severe OHSS occurred in two
cycles of the GnRH agonist trigger group and four cycles of the hCG
trigger group (11% vs. 6%, p ¼ 0.237).
Twelve out of the 19 patients in the GnRH agonist trigger group
and 13 out of the 63 patients exhibited simultaneous AFCs 15 and
AMHs 3.4 ng/mL. Regarding the general data, the women in the
GnRH agonist group were older than those in the hCG group
(33.8 ± 4.9 years vs. 33.2 ± 3.4 years, p ¼ 0.04), but BMI, Day 3 FSH,
AMH, AFC, FSH dose used, and hCG day E2 were similar (Table 3).
The clinical pregnancy rates of the GnRH agonist and the hCG
groups were 50% and 62%, respectively (p ¼ 0.44). The OHSS rates
were 25% and 23% (p ¼ 0.83) in the GnRH agonist and hCG groups,
respectively (Table 4).Table 3
Basic data for the patients who simultaneously met the inclusion criteria of AFC 15
and AMH level 3.4 ng/mL.
GnRH agonist
(n ¼ 12)
hCG group
(n ¼ 13)
pa
Age (y) 33.8 ± 4.9 33.2 ± 3.4 0.04*
BMI 20.8 ± 2.6 21.3 ± 2.3 0.74
Day 3 FSH (mIU/mL) 7.0 ± 1.9 7.0 ± 1.6 0.87
AMH (ng/mL) 7.7 ± 3.6 6.1 ± 2.1 0.15
AFC 15.7 ± 3.0 12.1 ± 2.5 0.99
FSH dose used (IU) 1395 ± 461 1628 ± 343 0.33
hCG Day E2 (pg/mL) 2635 ± 994 1930 ± 810 0.35
Values are expressed as mean ± standard deviation.
AFC ¼ antral follicle count; AMH ¼ anti-Müllerian hormone; BMI ¼ body mass in-
dex; FSH ¼ follicle-stimulating hormone; hCG ¼ human chorionic gonadotropin;
GnRH ¼ gonadotropin-releasing hormone.
a Calculated by t test.Discussion
The risk factors for OHSS include young age, low BMI, polycystic-
ovary pictures, high serum E2, multiple stimulated follicles, and
high AMH. E2 level had been thought to play a major role in OHSS
and had been suggested as an indicator of ovulation inductionwith
GnRH agonists. Lee et al [14] showed that an AMH cut-off value of
3.36 ng/mL provided a sensitivity of 90.5% and a speciﬁcity of 81.3%
in the OHSS prediction in a prospective study. This study also re-
ported that AMH is a better predictor of OHSS than E2 level. By
contrast, Kwee et al [13] showed that a cut off level of >14 antral
follicles provided the greatest sensitivity (82%) and speciﬁcity (89%)
and also the highest accuracy. We included patients with AMHs
>3.4 ng/mL or AFC >15 rather than using an E2-based threshold,
because the pathogenesis of OHSS relies on some vasoactive fac-
tors, particularly vescular endothelial growth factor (VEGF), that are
secreted by granulosa cells. Our total OHSS rate was 10.2%, which is
greater than the incidence in the general population.
Although the triggering of ovulation with GnRH agonists has
the advantages of FSH surges that are more similar to the natural
cycle and a lower rate of OHSS, early studies that used GnRH ag-
onists to trigger ovulation reported low pregnancy rates [3,5].
Previous studies of mammalian cycles have shown that the LH
surges induced by GnRH agonists are shorter in duration than
those induced with hCG, despite repeated GnRH agonist injections
[17,18]. Potential reasons for the lower ongoing pregnancy rates
following GnRH agonist triggering might be the adverse effects on
oocytes, embryos, or detrimental endometrium caused by the
shorter duration of the gonadotropin surge and defective corpus
lutea [17e19]. In our study, the numbers of metaphase II oocytes
yielded were similar between the two groups (GnRH agonist and
hCG: 11.3 ± 1.3 vs. 8.8 ± 0.7, respectively, p¼ 0.08). The numbers of
2PN embryos obtained from the two groups were also similar.
These ﬁndings are compatible with previous evidence that cycles
with GnRH agonist ovulation triggers exhibit good oocyte matu-
ration and embryo quality [3,20]. These ﬁndings supported the
notion that low pregnancy rates of the cycles triggered with the
GnRH agonist were not related to adverse effects on the oocytes
and embryos. Moreover, good pregnancy outcomes have also been
shown in donorerecipient cycles [20]. Detrimental effects on the
endometrium due either to direct effects of the GnRH agonist on
endometrial receptivity or defective corpus lutea seemed
responsible for the poor pregnancy outcome. The alternative
proposition is not plausible, because the long protocol used the
GnRH agonist to prevent premature LH surges without compro-
mising the pregnancy rate. As mentioned previously, the LH
duration was shorter in the GnRH agonist group, and LH function
was maintained by hCG for a longer period of time, due to its
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mal studies have shown that the withdrawal of LH can cause
irreversible luteolysis and further malfunction of the corpus
luteum [21,22]. Some studies have reported lower steroid hor-
mone levels and shorter luteal phases when GnRH agonists are
used to trigger ovulation [6,10]. The abrupt decrease in steroid
hormones also causes endometrial instability and compromises
[23]. Despite the lower concentration of estrogen and progester-
one in cycles that are triggered with GnRH agonists, the levels are
still supraphysiological and suppress LH production. This different
steroid pattern combined with the shorter duration of the LH
surge, causes the follicles to fail to develop corpus lutea or early
luteolysis [10]. For the above reasons, modiﬁed luteal support was
proposed to rescue the irreversible effect of luteolysis in cycles
with GnRH agonist triggers following ovarian stimulation.
Methods for modiﬁed luteal support that have been detailed in
previous studies include low dose hCG, LH, and intensive estrogen
and progesterone [7,8,10,11]. Previous studies have concluded that
low dose hCG for luteal support can reduce the occurrence of OHSS
without compromising the pregnancy rate. A review conducted by
Engmann and Benadiva [19] also reported good clinical and
ongoing pregnancy rates with low OHSS rates of 0% in normal re-
sponders and 7.7e8.3% in high responders. In our group, we used
two doses of recombinant hCG (250 mg) in the hCG triggering
group, while urinary hCG (1500 IU to 5000 IU) with intensive
estradiol and progesterone were given to the GnRH agonist-
triggered group. The OHSS rates were 16% in the GnRH agonist
group and 8% in the hCG group when the patients' AMHs were
>3.4 ng/mL or their AFCs were >15. There was no statistically sig-
niﬁcant difference and the occurrence of OHSS in the GnRH agonist
group was not decreased compared to the hCG group. This result
contrasts with the results of previous studies that have used low
dose hCG for luteal support [3,5,7,24]. The reasons for this
discrepancy might be that we included high-risk patients, used
different criteria, and examined a small number of patients in our
study group. One of the most important reasons for this discrep-
ancy might be the overdose of hCG that was used for luteal support.
A study published by Castillo et al [7] found that the occurrence of
OHSS is associated with the hCG dose used for luteal support [7]. In
our data, the occurrence was not related to hCG dose. This ﬁnding is
possibly related to the fact that the lowest dose of hCG used in our
study was above the threshold for decreasing the occurrence of
OHSS. The lowest hCG dose that prevents the occurrence of OHSS
without compromising pregnancy rate should be established with
further study. Another strategy that should be considered is the
freezing of all embryos to achieve an hCG-free cycle. One pro-
spective study indicated that GnRH agonist-triggered cycles in
combination with freeze-all resulted in a 2% OHSS occurrence rate
and 37% cumulative pregnancy rate/patient in the high-risk group
[25]. Subsequently, another retrospective study compared fresh
transfer and freeze-all followed by one frozen embryo transfer
approaches in high-risk patients undergoing GnRH agonist-
triggered cycles, and found comparable pregnancy outcomes
without occurrence of OHSS [26].
In conclusion, we found that pregnancy rate was not compro-
mised when hCG was used for luteal support in GnRH agonist-
triggered cycles. However, the occurrence of OHSS might not be
reduced by GnRH agonist triggers when hCG was used for luteal
support. These ﬁndings indicate that other strategies for the pre-
vention of OHSS should be considered when GnRH agonists are
used to trigger ovulation. Further studies might determine the
amount of hCG that is required to reduce the OHSS while simul-
taneously maintaining a comparable pregnancy rate. Additionally,
the freezing of all embryos for frozen embryo transfer should be
considered.Conﬂicts of interest
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